Rebalix
UBS · sheet of 10 September 2026
UBS · sheet of 10 September 2026ETF sheet · official issuer and register data
UBS Global Gender Equality UCITS ETF hEUR acc
IE00BDR5H073 · IE00BDR5H073 · EUR · domicile Ireland
Equity · GlobalEUR-hedged share classSFDR art. 8
Index tracked: Solactive Equileap Global Gender Equality 100 Leaders Index Hedged in EUR
- TER
- 0.23%+ trans. 0.01%
- Fund size
- 19 m EUR
- Tracking difference
- +0.18%3-year avg
- 🇮🇹 tax rate
- 26.00%white list 0.00%
- Replication
- Physical (full replication)
- Income
- Accumulating
Launch 19 Dec 2017 · costs from the KID as of 2 Sept 2026 · 98 securities held · 9 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 5 Aug 2026
The Fund is passively managed and seeks to track performance of the The Solactive Equileap Global Gender Equality 100 Leaders Net Total Return hedged to EUR Index (the 'Index'). The Index is designed to generate exposure to the equity market performance of developed market companies which have a high gender diversity score while avoiding those with a low gender diversity score. This focus on companies with a high gender diversity score excludes at least 20% of the least well-rated securities as against the standard index universe. The Fund does not…
Performance since series start (in euro) — base 100
19 Dec 2017 → 8 Sept 2026 · dividends reinvested where declared by the issuer
Returns in euro
| 1 year | +12.3% |
| 3 years | +47.7% |
| 5 years | +43.1% |
| 10 years | series too young |
| Since series start | +105.9% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 9.26% | 9.88% | 11.58% |
| Max drawdown | −7.12% | −12.63% | −19.58% |
| Sharpe | 1.04 | 1.04 | 0.47 |
| Sortino | 1.57 | 1.48 | 0.66 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · IE00BDR5H073 · IE00BDR5H0731
RebalixIE00BDR5H073 · IE00BDR5H073 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +15.80% | +15.63% | +0.18% |
| 2024 | +11.10% | +10.94% | +0.16% |
| 2023 | +14.19% | +13.99% | +0.20% |
| 2022 | −10.17% | −10.33% | +0.16% |
| 2021 | +17.92% | +17.93% | −0.01% |
Holdings
Portfolio as declared by the issuer · 19 Aug 2026 · 98 securities · top-10 weight = 14.5%
| Top holdings | Weight |
|---|---|
| 1.8% | |
| 1.7% | |
| 1.6% | |
| 1.4% | |
| 1.4% | |
| 1.4% | |
| 1.4% | |
| 1.3% | |
| 1.3% | |
| 1.3% |
Countries (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
GENDEE · Borsa Italiana (ETFplus)
GGUE · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 5 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
Prospectus · www.ubs.com/2/e/files/ubs_irl_etf_plc_peit.pdf
The live sheet, always up to date
rebalix.com/en/etf/IE00BDR5H073
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00BDR5H073
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · IE00BDR5H073 · IE00BDR5H0732